Clinical trials: Sexually Transmitted Disease (STD)
HIV Infections, Risk Reduction
Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study
PrEP (pre-exposure prophylaxis) is an effective prevention strategy in which HIV-negative individuals take antiretroviral drugs (tenofovir disoproxil fumarate and emtricitabine - TDF/FTC) to reduce HIV acquisition.
- Conditions
- HIV Infections, Risk Reduction, Risk Behavior, Risky Health Behavior
- Trial name
- Seroincidence (NCT05674682)
- Testing
- HIV testing
- Where
- 2 sites in Brazil
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Evandro Chagas National Institute of Infectious Disease
Osteoporosis
HIV UPBEAT: Understanding the Pathology of Bone Disease in HIV-infected Patients.
Despite the prevalence of osteopenia and osteoporosis in the HIV positive population, relatively little is known about the underlying pathology.
- Trial name
- UPBEAT (NCT01778361)
- Where
- Ireland
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University College Dublin
HIV Infections
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same dose of buprenorphine for at least 3…
- Trial name
- NCT00571961
- Testing
- Kaletra (lopinavir/ritonavir), buprenorphine, Clinical evaluations/Blood draws
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV, HIV Infections
Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study
The purpose of the study is to look at the levels of three HIV medications darunavir, ritonavir and atazanavir in the blood after the drug intake has been stopped in order to understand how long these drugs persist in blood for.
- Trial name
- NCT01073761
- Testing
- darunavir/ritonavir then atazanavir/ritonavir
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- St Stephens Aids Trust
HIV Infection
Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
This is a single-site substudy, "Investigation of the Effect of Cenicriviroc (CVC) plus Emtricitabine/Tenofovir (FTC/TDF) on Atherosclerosis Risk Factors", open to all patients enrolled in the primary study, "A Phase 2b…
- Trial name
- NCT01474954
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Francisco
HPV Infection
Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial
A 3-dose HPV vaccination scheme has shown to be safe and immunogenic in people living with HIV (PLWH), although evidence on 1-dose, which is important to improve coverage, is scarce.
- Trial name
- H2VICTORY (NCT05173324)
- Testing
- HPV vaccine, HPV testing, HAV vaccine
- Volunteers
- 8,000 people
- Sponsor
- International Agency for Research on Cancer
Infection, Human Immunodeficiency Virus
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
- Trial name
- NCT02859259
- Testing
- BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC
To show that zalcitabine (dideoxycytidine; ddC) is at least as effective as zidovudine (AZT) in the treatment of AIDS or advanced AIDS related complex (ARC), and also that ddC shows a different safety profile than AZT.
- Trial name
- NCT00000679
- Testing
- Zidovudine, Zalcitabine
- Where
- 25 sites in United States
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Acquired Immunodeficiency Syndrome
Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients
This study will examine how quickly white blood cells called CD4 lymphocytes reproduce and how long they live in people infected with HIV.
- Trial name
- NCT00001650
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
- Conditions
- Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection
- Trial name
- anal HSIL HIV- (NCT05555862)
- Testing
- Artesunate
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Frantz Viral Therapeutics, LLC
HIV Infections
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients.
- Trial name
- NCT00144170
- Testing
- Tipranavir (with low dose ritonavir), Comparator protease inhibitor(CPI)/low dose ritonavir(r)
- Where
- 174 sites in Argentina, Austria and 15 more
- Volunteers
- 882 people
- Sponsor
- Boehringer Ingelheim
Genital Warts
Efficacy and Safety of Oral Ivermectin for Genital Warts
This study aims to evaluate the efficacy and safety of oral ivermectin in adults with recalcitrant genital warts that have not responded to conventional treatments.
- Trial name
- NCT07913321
- Testing
- Ivermectin
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- University of Health Sciences Lahore
HIV/AIDS
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
The purpose of the study is to evaluate the safety, acceptability, and PK/PD profile of maraviroc gel following rectal and vaginal administration. The study also includes oral exposure to maraviroc.
- Trial name
- NCT02346084
- Testing
- Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label…
- Trial name
- SIGNET (NCT01231555)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Efavirenz 600 mg once daily
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- ViiV Healthcare
HIV-1-infection, HIV Infections
Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV
This study is a phase II, multicenter, randomized, blind, placebo-controlled to evaluate the safety, tolerance, efficacy of ASC22 injection in combination with anti-retroviral therapy to treat subjects living with human…
- Conditions
- HIV-1-infection, HIV Infections, PD-L1 Gene Mutation
- Trial name
- NCT05330143
- Testing
- ASC22 1mg/kg, ASC22 2.5mg/kg, Antiretroviral Therapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Cervical Cancer
Web-Based Education Program and Educational Booklet Developed on Cervıcal Cancer
Cervical cancer is the fourth most common cancer type among women worldwide and ranks ninth in Turkey, making it the second most common gynecological cancer.
- Trial name
- NCT06705309
- Testing
- Web-Based Education
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
HIV Infection, Lymphatic Filariasis
Interaction Between HIV and Lymphatic Filariasis
The impact of lymphatic filariasis (LF) on HIV is assessed by measuring HIV viral load before and after DEC treatment of filariasis in double-infected individuals.
- Trial name
- NCT00295698
- Testing
- Diethylcarbamazine
- Sponsor
- DBL -Institute for Health Research and Development
HIV Infections
A Peer-Driven Intervention to Increase PrEP Uptake Among Minority MSM
The objective of this study is to develop an effective peer-driven intervention (PDI) approach and assess its feasibility and efficacy on pre-exposure prophylaxis (PrEP) uptake among men who have sex with men.
- Trial name
- NCT05161663
- Testing
- Peer-driven intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- The Miriam Hospital
Bone Demineralization
Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss
Antiretroviral therapy (ART) initiation is associated with a significant loss of bone mineral density (BMD), characterised by increases in bone turnover, which is largely limited to the first 48 weeks of therapy.
- Trial name
- APART (NCT02322099)
- Testing
- Alendronate, calcium carbonate and colecalciferol, Tenofovir disoproxil
- Where
- 2 sites in Ireland
- Volunteers
- 53 people
- Sponsor
- University College Dublin
HIV Infections
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it.
- Trial name
- NCT00076063
- Testing
- ALVAC-HIV (vCP1452), LIPO-5
- Where
- 11 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.